Imatinib for patients with liver or kidney dysfunction: no need to modify the dose.
Judson
Ian R
IR
D000284:Administration, Oral; D001549:Benzamides; D017321:Clinical Trials, Phase I as Topic; D016903:Drug Monitoring; D006801:Humans; D000068877:Imatinib Mesylate; D007674:Kidney Diseases / Q000188:drug therapy*; D008107:Liver Diseases / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011743:Pyrimidines / Q000008:administration & dosage*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate